Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop hopes to soothe dry eye sufferers

NCT ID NCT07656688

Symptom relief Sponsor: Huons Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests a new eye drop called HUC1-394 in 150 adults with moderate to severe dry eye disease. Participants will use the drops or a placebo for a period to see if the drug reduces eye surface damage and improves symptoms. The goal is to find the best dose and frequency.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HUC1-394 eye drops
What this could lead to
If it works, this could lead to a new treatment option for people with moderate to severe dry eye disease, reducing eye damage and discomfort.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Why investors are watching

Huons is running a phase 2 trial of its dry eye drug HUC1-394 in 150 patients with moderate to severe disease. The trial compares different dosing frequencies against a placebo to find the best dose. For a small company, this readout is a key test of whether the drug works and is safe enough to keep developing.

If it works: A positive result could show HUC1-394 eases dry eye symptoms better than placebo, giving Huons a viable product candidate to advance toward later-stage trials. That would strengthen the company's pipeline and its position in the eye care market.

If it fails: The trial could fail to show a clear benefit over placebo, or safety issues could emerge, which would likely end the drug's development. Phase 2 trials often fail, so a negative result is a real possibility for Huons.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥ 19 years at the time of screening * Trial participants who have experienced at least one of the following dry eye disease symptoms for at least 3 months prior to the time of screening * Trial participants who meet all of the following criteria in at least one eye (left or right) at the time of screening and randomization: TCSS (NEI grading) ≥ 4 / Non-anesthetic Schirmer test result \> 0 mm and ≤ 10 mm/5 min / TBUT \< 7 seconds * OSDI score ≥ 23 at the time of screening * Trial participants who have provided voluntary written informed consent after receiving a full explanation and understanding of the clinical trial Exclusion Criteria: * Trial participants with clinically significant ophthalmic diseases that may confound the interpretation of clinical trial results * Trial participants with blepharospasm, entropion, ectropion, or abnormalities of the eyelashes * Trial participants with any active ophthalmic disease that may affect the ocular surface, such as active allergy, anterior uveitis, and Stevens-Johnson syndrome * Trial participants with a history of corneal transplantation or neurotrophic keratitis * Trial participants with autoimmune diseases or immunodeficiency disorders * Pregnant or lactating women, or women of childbearing potential and men of reproductive potential who plan to conceive during the clinical trial or are unwilling to use an appropriate method of contraception * Trial participants who have participated in another clinical trial and received an investigational product or used an investigational medical device within 30 days prior to the time of screening * Trial participants who are deemed ineligible for participation by the investigator for any other reason in the clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease (DED) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease (DED)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.